Greg Gibson

Regents Professor

Georgia Tech
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Many non-coding variants influence complex traits and diseases through gene regulation, yet the mechanisms linking these variants to downstream biology remain poorly understood. Here, we present eQTLGen Phase 2 , a comprehensive genome-wide analysis of gene expression quantitative trait loci (eQTLs) in 43,301 blood samples from 52 datasets. Beyond local cis -effects, this sample size enabled the first systematic mapping of trans -eQTLs at scale. We identify cis -eQTLs for nearly all expressed genes (94.7%) and trans -eQTLs for over half (56.2%). Second, by colocalizing cis -eQTLs with trans -eQTLs, we infer a directed gene regulatory network comprising 47,554 directed gene regulatory relationships. These networks reveal how genetic perturbations in upstream regulators produce dose-dependent downstream effects, supported by Perturb-seq and ChIP-seq data. Third, integrating this network with 87 genome-wide association studies allows us to systematically prioritize trait-relevant pathways and candidate genes. Variants exerting both cis – and trans -effects are markedly more likely to colocalize with trait associations than cis -only variants, delineating a subset of functionally active cis -eQTLs from a large group with limited downstream impact. This distinction provides a conceptual framework for identifying regulatory variants that truly mediate complex trait biology. Together, these results provide a publicly available resource of cis – and trans -eQTLs and an in vivo scaffold for human gene-regulatory networks, elucidating how propagation of cis -effects modulates complex disease.

Year:

2026

Genetically transitional disease (GTD) is emerging as a new concept in genomic medicine to straddle between the traditional binary classification of monogenic and polygenic disease. Genetic testing result reports in molecular laboratories have been predicated on the monogenic disease model, which focuses on pathogenic and likely pathogenic variants. While variants of uncertain significance (VUS) are reported by laboratories, there are challenges with regard to their clinical application so that these variants are often dismissed by ordering physicians. Unlike Mendelian disorders, where genetic variants are of high penetrance and highly probabilistic, the GTD concept is employed to highlight the impact of low-to-moderate effect gene variants whose influence on disease is modified by the genetic background. The GTD concept may explain health conditions associated with variants that are necessary but not sufficient for pathogenesis, lying in the mid gray zone between Mendelian and polygenic diseases. Although VUSs may not reach the level of pathogenicity based on American College of Medical Genetics and Genomics guidelines, they could be provisionally classified as GTD-associated variants to annotate and interpret the relationship between VUS and human genetic disease. The appropriate implementation of the GTD concept could impact patient care and research by focusing attention on the individual variability of responses in various diseases.

Year:

2025

Background Single cell multi-omic investigation opens-up new opportunities to understand mechanisms of gene regulation. Existing methods for inferring transcript abundance from chromatin accessibility fail to prioritize the most relevant peaks and tend to assume positive associations between ATAC peaks and RNA counts. We hypothesize that gene regulation can be modeled as a function of combined positive and negative interactions among peaks and that causal regulatory variants are enriched in the vicinity of the most critical peaks. Results A machine learning pipeline leveraging single nuclear multiomic transcriptome and chromatin accessibility data is developed to model gene expression as a function of ATAC peak intensity. Multiome data was available for 18 immune cell types from 29 donors, 19 with Crohn’s disease. The pipeline aggregates results from three machine learning approaches (random forest regression, XGBoost, and Light GBM) as well as linear regression to identify which ATAC peaks contribute to explaining variation among donors and cell types in pseudobulk gene expression. The coefficient of determination with cross-validation was used to identify robust models which typically explain between 5% and 40% of transcript abundance, utilizing on average 47% of the ATAC peaks, representing a significant gain in predictive accuracy. The most important peaks are enriched in GWAS variants for inflammatory bowel disease and the autoimmune disease systemic lupus erythematosus, but not for rheumatoid arthritis. Conclusion Atlanta Plots visualize the proportion of ATAC peaks contributing to a predictive model of gene expression as well as the proportion of variance explained by the model. Software implementing our pipeline, “snATAC-Express”, is freely available on GitHub.

Year:

2025

Knee-Osteoarthritis (Knee-OA) is a prevalent joint disorder lacking FDA-approved cell-therapies to halt its progression. This study uses single-cell RNA sequencing to analyze bone marrow aspirate concentrate (BMAC) and stromal vascular fraction (SVF) samples in a clinical trial of autologous cell therapies. Trial site-specific variability was significant in BMAC, necessitating tailored normalization, whereas SVF was less affected, likely due to uniform subcutaneous fat sampling. Variance partitioning and tensor decomposition identified site effects in BMAC but revealed shared pathways across cell types in both tissues. Differential gene expression (DEG) analysis between responders and non-responders yielded no significant findings, though likelihood ratio testing (LRT) revealed enrichment for DEG patterns linked to disease severity, potentially masked by patient heterogeneity. Key BMAC pathways included oxidative phosphorylation, unfolded protein response, and TNFα signaling. Cell-cell communication analysis suggested enhanced HLA signaling in non-responder MSCs, consistent with inflammation, while responders showed more coordinated immune interactions. BMAC-MSCs promoted chondrocyte proliferation, whereas SVF-MSCs emphasized immune regulation. Variability in therapy outcomes reflects patient heterogeneity beyond genomic factors, complicating the immediate use of genomic profiling to guide treatment. Nonetheless, as molecular pathways are better understood, integrating genomic insights into personalized strategies may become feasible.

Year:

2025

Genome-wide association studies typically identify hundreds to thousands of loci, many of which harbor multiple independent peaks, each parsimoniously assumed to be due to the activity of a single causal variant. Fine-mapping of such variants has become a priority and since most associations are located within regulatory regions, it is also assumed that they colocalize with regulatory variants that influence the expression of nearby genes. Here we examine these assumptions by using a moderate throughput expression CROPseq protocol in which Cas9 nuclease is used to induce small insertions and deletions across the credible set of SNPs that may account for expression quantitative trait loci (eQTL) for genes associated with inflammatory bowel disease (IBD). Of the 4,384 SNPs targeted in 88 loci (an average of 50 per locus), 439 were significant and further examined for validation. From these, 98 significantly altered target gene expression in HL-60 myeloid cell line, 74 in induced macrophages from these HL-60 cells, and 78 in induced neutrophils for a total of 201 validated effects (46%), 43 of which were observed in at least two of the cell types. Considering the observed sensitivity and specificity of the controls, we estimate that there are at least 150 true positives per cell type, an average of almost 2.4 for each of the 64 eQTL for which putative causal variants have been fine-mapped. This implies that haplotype effects are likely to explain many of the associations. We also demonstrate that the same approach can be used to investigate the activity of very rare variants in regulatory regions for 89 genes, providing a rapid strategy for establishing clinical relevance of non-coding mutations.

Year:

2025

At the beginning of the COVID-19 pandemic, the Georgia Institute of Technology made the decision to keep the university doors open for on-campus attendance. To manage COVID-19 infection rates, internal resources were applied to develop and implement a mass asymptomatic surveillance program. The objective was to identify infections early for proper follow-on verification testing, contact tracing, and quarantine/isolation as needed. Program success depended on frequent and voluntary sample collection from over 40,000 students, faculty, and staff personnel. At that time, the nasopharyngeal (NP) swab, not saliva, was the main accepted sample type for COVID-19 testing. However, due to collection discomfort and the inability to be self-collected, the NP swab was not feasible for voluntary and frequent self-collection. Therefore, saliva was selected as the clinical sample type and validated. A saliva collection kit and a sample processing and analysis workflow were developed. The results of a clinical sample-type comparison study between co-collected and matched NP swabs and saliva samples showed 96.7% positive agreement and 100% negative agreement. During the Fall 2020 and Spring 2021 semesters, 319,988 samples were collected and tested. The program resulted in maintaining a low overall mean positivity rate of 0.78% and 0.54% for the Fall 2020 and Spring 2021 semesters, respectively. For this high-throughput asymptomatic COVID-19 screening application, saliva was an exceptionally good sample type.

Year:

2024

Year:

2024

By analyzing two large atlases of almost 4 million cells, we show that immune‐senescence involves a gradual loss of cellular identity, reflecting increased cellular heterogeneity, for effector, and cytotoxic immune cells. The effects are largely similar in both males and females and were robustly reproduced in two atlases, one assembled from 35 diverse studies including 678 adults, the other the OneK1K study of 982 adults. Since the mean transcriptional differences among cell‐types remain constant across age deciles, there is little evidence for the alternative mechanism of convergence of cell‐type identity. Key pathways promoting activation and stemness are down‐regulated in aged T cells, while CD8 TEM and CD4 CTLs exhibited elevated inflammatory, and cytotoxicity in older individuals. Elevated inflammatory signaling pathways, such as MAPK and TNF‐alpha signaling via NF‐kB, also occur across all aged immune cells, particularly amongst effector immune cells. This finding of lost transcriptional identity with age carries several implications, spanning from a fundamental biological understanding of aging mechanisms to clinical perspectives on the efficacy of immunomodulation in elderly people.

Year:

2024

The transferability of polygenic scores across population groups is a major concern with respect to the equitable clinical implementation of genomic medicine. Since genetic associations are identified relative to the population mean, inevitably differences in disease or trait prevalence among social strata influence the relationship between PGS and risk. Here we quantify the magnitude of PGS-by-Exposure (PGSxE) interactions for seven human diseases (coronary artery disease, type 2 diabetes, obesity thresholded to body mass index and to waist-to-hip ratio, inflammatory bowel disease, chronic kidney disease, and asthma) and pairs of 75 exposures in the White-British subset of the UK Biobank study (n=408,801). Across 24,198 PGSxE models, 746 (3.1%) were significant by two criteria, at least three-fold more than expected by chance under each criterion. Predictive accuracy is significantly improved in the high-risk exposures and by including interaction terms with effects as large as those documented for low transferability of PGS across ancestries. The predominant mechanism for PGS×E interactions is shown to be amplification of genetic effects in the presence of adverse exposures such as low polyunsaturated fatty acids, mediators of obesity, and social determinants of ill health. We introduce the notion of the proportion needed to benefit (PNB) which is the cumulative number needed to treat across the range of the PGS and show that typically this is halved in the 70 th to 80 th percentile. These findings emphasize how individuals experiencing adverse exposures stand to preferentially benefit from interventions that may reduce risk, and highlight the need for more comprehensive sampling across socioeconomic groups in the performance of genome-wide association studies.

Year:

2024

Year:

2023

Collaborators (54)

Qingbo Wang

Associate Professor

University of Tokyo

JAPAN
View details

Annique Claringbould

Assistant Professor

Erasmus MC

NETHERLANDS
View details

Marie Loh

Assistant Professor

Lee Kong Chian School of Medicine

SINGAPORE
View details

Buhle Moyo

Assistant Research Professor

Rice University

UNITED STATES
View details

Javier Martin

Professor

Instituto de Parasitología y Biomedicina López-Neyra

SPAIN
View details

Katie Burnham

University of Oxford

UNITED KINGDOM
View details

Sini Nagpal

Assistant Professor

Indian Institute of Technology, Bombay

View details

Brenda WJH Penninx

Professor

-

NETHERLANDS
View details

René Pool

University of Amsterdam

NETHERLANDS
View details

Markus Scholz

Leipzig University

GERMANY
View details

Farzana Jasmine

Staff Scientist

University of Chicago

UNITED STATES
View details

Marta Eugenia Alarcón Riquelme

Scientific Director

Centro Pfizer - Universidad de Granada - Junta de Andalucía de Genómica e Investigación Oncológica

SPAIN
View details

Laura Raffield

Assistant Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Dirk Paul

Interim Head of PMB BioPharma

AstraZeneca UK Limited

UNITED KINGDOM
View details

Vasantha Kolachala

Associate Scientist

Emory University

UNITED STATES
View details

Jouke-Jan Hottenga

Senior Researcher

Hamad Bin Khalifa University

QATAR
View details

Roel A. Ophoff

Professor

University of California, Los Angeles

UNITED STATES
View details

Ana Viñuela

Academic, Lecturer (Teaching and Research)

University of Dundee

UNITED KINGDOM
View details

Pashupati Mishra

Tampere University

FINLAND
View details

Emma Elisabeth Davenport

Group Leader

Wellcome Sanger Institute

UNITED KINGDOM
View details

José Manuel Soria Fernández

Principal Investigator. Head of Group

Hospital de la Santa Creu i Sant Pau

SPAIN
View details

Julian Knight

University of Oxford

UNITED KINGDOM
View details

Krishnendu Roy

Dean of Engineering

Vanderbilt University

UNITED STATES
View details

Mika Kähönen

University of Tampere

FINLAND
View details

Muhammad Kibriya

Research Associate Professor

University of Chicago

UNITED STATES
View details

Alexander Teumer

Professor

University Medicine Greifswald

GERMANY
View details

Andrew Brown

Principal Investigator

University of Dundee

UNITED KINGDOM
View details

Toni Boltz

Massachusetts General Hospital

UNITED STATES
View details

Zoltán Kutalik

Full Professor

University of Lausanne

SWITZERLAND
View details

Subra Kugathasan

Professor

Emory University

UNITED STATES
View details

Katja Pahkala

Associate professor, Academy research fellow

University of Turku

FINLAND
View details

Emma Raitoharju

Senior Researcher

University of Tampere

FINLAND
View details

Grant Montgomery

Professorial Research Fellow

University of Queensland

AUSTRALIA
View details

Annette Peters

Chair of Epidemiology

Ludwig-Maximilians-Universität München

GERMANY
View details

Kaur Alasoo

Associate Professor

University of Tartu

ESTONIA
View details

Joachim Thiery

Dean of Medicine and UKSH Board for Research snd Education

Kiel University

GERMANY
View details

Alexis Battle

Professor

Johns Hopkins University

UNITED STATES
View details

Holger Kirsten

Leipzig University

GERMANY
View details

Olli T. Raitakari

University of Turku

FINLAND
View details

Uwe Völker

Professor, Head of Department

Universitätsmedizin Greifswald

GERMANY
View details

Jan Veldink

Professor of Neurology and Neurogenetics

University Medical Center Utrecht, Utrecht University

NETHERLANDS
View details

Suvi Rovio

Adjunct professor, senor researcher

University of Turku

FINLAND
View details

Carlos Cruchaga

Professor

Washington University in St. Louis

UNITED STATES
View details

Carla van der Kallen

University of Maastricht

NETHERLANDS
View details

qingping yao

Chief, Rheumatology, Professor

Stony Brook University

UNITED STATES
View details

Robert Hogan

Professor

University of Georgia

UNITED STATES
View details

Terho Lehtimäki

University of Tampere

FINLAND
View details

Gang Bao

Rice University

UNITED STATES
View details

Yukinori Okada

University of Tokyo

JAPAN
View details

Marleen van Greevenbroek

University of Maastricht

NETHERLANDS
View details

Ciaran Lee

Lecturer

University College Cork

IRELAND
View details

Yun Li

Professor

University of North Carolina

UNITED STATES
View details

Dorret I Boomsma

Full professor

University of Amsterdam

NETHERLANDS
View details

Takanori Hasegawa

Associate Professor

Institute of Science Tokyo

JAPAN
View details